AGM 2026

Sep 7, 2026

Summary

MCS-2 is highlighted for its unique action and safety in treating benign prostatic hyperplasia, with the company among the first to secure FDA phase III approval for a botanical drug, positioning it for early market entry.

Speaker 1

I think the MCS-2 product is unique in its mechanism of action. It will bring about help to many patients for benign prostatic hyperplasia, where currently there is no treatment that can serve their needs. I think that the safety profile is remarkable, and based on this alone, it will stand out as a unique product and very specialized in this space.

Speaker 2

Have become one of the first five companies to get a phase III clinical trial approved by FDA, by U.S. FDA, and could be one of the first five companies to have a botanical drug approved by the U.S. FDA.

Speaker 3

MCS-2.